Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection

2016 ◽  
Vol 23 (9) ◽  
pp. 677-686 ◽  
Author(s):  
E. Gray ◽  
A. O'Leary ◽  
J. A. Kieran ◽  
E. Fogarty ◽  
T. Dowling ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Direct Costs ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Eric G. Meissner ◽  
Amy Nelson ◽  
Miriam Marti ◽  
Henry Masur ◽  
Anu Osinusi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Virologic Response ◽  
Antiviral Agents ◽  
Virologic Response ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Abstract Successful treatment of chronic hepatitis C virus infection can now be achieved using direct-acting antiviral agents without interferon. In this report, we present a patient who achieved a sustained virologic response after 27 days of treatment with sofosbuvir and ribavirin. It is imperative to identify factors that allow for shorter treatment times in some individuals.

scholarly journals Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions

2018 ◽  
Vol 21 (1s) ◽  
pp. 271s-308s ◽  
Author(s):  
Samantha Myers ◽  
Gurleen Khosa ◽  
I fan Kuo ◽  
Donica Janzen ◽  
Silvia Alessi-Severini
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Financial Burden ◽  
Universal Coverage ◽  
Hepatitis C Infection ◽  
Coverage Criteria ◽  
Direct Acting Antiviral ◽  
Canadian Provinces ◽  
Direct Acting

Background: Direct-acting antivirals (DAAs) have become the standard treatment for patients with chronic hepatitis C infections because of their high cure rates and favourable side effect profiles; however, access to this new class of agents has been limited because of its high cost.  Public payers across Canada have implemented strict criteria for drug coverage in order to contain expenditures. Efforts have been made to improve access to medication for this high-burden condition. Recent coverage criteria across national and international jurisdictions have been compared.Methods: Coverage criteria for several DAAs were reviewed by accessing Canadian provincial drug formularies. International coverage (e.g., Europe, Australia, United States, Egypt, India) was reviewed by searching available literature. Results: Coverage criteria vary across Canada. By April 2018, most Canadian jurisdictions had removed the stage 2 liver fibrosis requirement for patients to be eligible for coverage. Internationally, patients’ access to DAAs differs significantly. Many jurisdictions restrict DAA prescribing authority to specialists and request documentation of chronic hepatitis C. In the US, considerable gaps of coverage are identifiable and patients might face significant financial burden to receive treatment. Conclusion: DAAs appear to be generally accessible through public drug plans in Canada compared to other countries.

Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy

2019 ◽  
Vol 53 (5) ◽  
pp. 559-563 ◽  
Author(s):  
Simone Lanini ◽  
Paola Scognamiglio ◽  
Raffaella Pisapia ◽  
Claudia Minosse ◽  
Alessandro Agresta ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document